Psy136 - A Comparison of P&r Requirements for Orphan Drugs in 25 Markets

Value in Health - United Kingdom
doi 10.1016/j.jval.2018.09.2710
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Psy60 - Orphan Versus Ultra-Orphan Drugs Prices in England

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Psy59 - Orphan Drugs Prices Comparison in Middle East North Africa (Mena) Region

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Determinants of Orphan Drugs Prices in France: A Regression Analysis

Orphanet Journal of Rare Diseases
MedicineGeneticsPharmacology
2017English

Psy150 - Inequity of Orphan Drugs Prices in Europe

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Pivotal Studies of Orphan Drugs Approved for Neurological Diseases

Annals of Neurology
Neurology
2009English

Access to Orphan Drugs: A Cross Country Comparison of Legislative Approach Among Serbia, Croati a and Macedonia

Acta Medica Medianae
2018English

Comparison of Recent Hta Appraisals of Orphan Drugs by Nice, SMC and Has in 2015-2017

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2017English

PHP46 Market Uptake of Orphan Drugs – A European Analysis

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2011English

Mechanism of Coordinated Access to Orphan Drugs

Orphanet Journal of Rare Diseases
MedicineGeneticsPharmacology
2012English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy